argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
argenx (Euronext & Nasdaq: ARGX), a global immunology company focused on severe autoimmune diseases, has announced its participation in the 43rd Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
argenx (Euronext & Nasdaq: ARGX), a global immunology company focused on severe autoimmune diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Tim Van Hauwermeiren, the company's CEO, will deliver a presentation on Monday, January 13, 2025 at 9:45 a.m. PT.
The presentation will be accessible through a live webcast on the Investors section of the argenx website (argenx.com/investors). A replay option will remain available on the company's website for approximately 30 days after the presentation.
Details
News Market Reaction – ARGX
The recorded move for ARGX in the trading session of this news was +3.88%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
January 6, 2025
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 a.m. PT.
A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube.
For further information, please contact:
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy (US)
aroy@argenx.com
Lynn Elton (EU)
lelton@argenx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.